Market Challenges And Opportunities

Global Migraine Therapeutic Market Drivers:

Rise in burden of to migraine to underpin market growth

One of the key factors expected to augment the growth of the global migraine therapeutic market during the forecast period is the rise in prevalence of migraine worldwide. For instance, headache disorders, including migraine, are the second-leading cause of years lived with disability (YLD) worldwide among men and women. According to National Center for Biotechnology Information, migraine affects more than one billion people each year worldwide, and is one of the most common neurologic disorders, with a high prevalence and morbidity, especially among young adults and females. Thus, there is an increase in demand for migraine therapeutics.

Increasing awareness among people to augment market growth

Another factor which is driving the growth of the global biosurgery market is the rise in awareness among individuals about migraine and its treatment options. For instance, migraines are a chronic neurological disorder that affects around one billion people around the world. With the increase in awareness among people, the demand for migraine therapeutics is also increasing. Every year, the United Kingdom observes Migraine Awareness Week in the first week of September. In 2023, it will be observed from September 4 to 13. Purple is the official color of the National Migraine and Headache Awareness Month (MHAM).

Global Migraine Therapeutic Market Restraints:

Side effects of migraine drugs to hinder market growth

One of the key factors expected to hamper the growth of the global migraine therapeutic market is the adverse effects of migraine drugs. Common adverse effects include nausea/vomiting, diarrhea, drowsiness, headache, tingling or numbness in toes, and tightness or discomfort in the chest/throat. Sleepiness and fatigue are also common in migraine patients. The other less frequently mentioned side effects include muscle weakness, warm sensations, and chest pressure. NSAIDS (nonsteroidal anti-inflammatory drugs like ibuprofen) are the first line of treatment when it comes to migraines, and are the safest medication for migraines.

Increasing undiagnosed cases to hamper market growth

Another factor which is hampering the growth of the global migraine therapeutic market is the lack of proper diagnosis and increasing undiagnosed cases. Migraines are often undiagnosed and untreated. If there are regular signs/symptoms of migraine, it is important to make an appointment with the doctor to discuss ways to treat and manage migraines. It is also important to get medical help immediately if the headache feels different from the usual migraine headaches. Moreover, the lack of consultation for headache is also found to be a major contributing factor to underdiagnosed cases. This in turn is restraining the growth of the market.

Figure 2. Global Migraine Therapeutic Market Share (%), by Therapeutics, 2022

Global Migraine Therapeutic Market Opportunities:

Increase in demand for safe and effective treatment across the globe is expected to offer significant growth opportunities for players in the migraine therapeutic market. For instance, with the increase in burden of migraine and increase in awareness, the demand for safe and effective treatment is also increasing rapidly. In January 2022, BioDelivery Sciences announced the launch of new drug, Elyxyb (celecoxib oral solution), a fast-acting liquid. Elyxyb is one of the first U.S. Food and Drug Administration (FDA) approved ready-to-use oral solutions for adults in the treatment of migraine, with or without aura. This in turn is driving the market growth.

Rise in research and development (R&D) around the world is expected to offer significant growth opportunities for players in the global migraine therapeutic market. For instance, in April 2020, Novartis announced that clinical data for Aimovig (erenumab) was reported in Neurology. Real-world evidence supports benefits seen in Aimovig clinical trials. This data strengthens the role of Aimovig as a preventive migraine treatment and confirms its real-world and long-term safety and efficacy benefit in patients with episodic and chronic migraine. This in turn is expected to augment the growth of the global migraine therapeutic market.